Procter & Gamble Health Ltd. (PGHL) AI Stock Analysis

• Market Cap: ₹103.18B
• Dividend Yield: 2.97%
• Average Volume (3M): 481.00
• Price to Earnings (P/E): 34.3
• Beta (1Y): 0.47
• Revenue Growth: 2.37%
• EPS Growth: 23.22%
• Country: IN
• Employees: 1,336
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 39.87
• Shares Outstanding: 16,599,382
• 10 Day Avg. Volume: 424
• 30 Day Avg. Volume: 481
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹7,047.00
• Price Target Upside: 13.37% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 75 Outperform
• Price Target: ₹7,047.00 ▲(13.37% Upside)

Procter & Gamble Health Ltd. exhibits strong financial performance with robust profitability and a stable balance sheet, which are the most significant factors contributing to the score. Technical analysis indicates a stable price trend with neutral market sentiment. The valuation is moderate, with a high P/E ratio balanced by a reasonable dividend yield. The absence of earnings call data and corporate events does not impact the score.

Procter & Gamble Health Ltd. Business Overview & Revenue Model

Company Description

Procter & Gamble Health Ltd. (PGHL) is a subsidiary of Procter & Gamble Company, specializing in health and wellness products. The company operates within the healthcare sector, focusing on a variety of consumer health products, including over-the-counter medications, dietary supplements, and oral health products. PGHL aims to improve consumer health and well-being through its scientifically backed and trusted product offerings.

How the Company Makes Money

PGHL generates revenue primarily through the sale of its health-related products, which are marketed under well-known brands. The company utilizes a multi-channel distribution strategy, including retail partnerships, e-commerce platforms, and direct-to-consumer sales. Key revenue streams include prescription and over-the-counter medications, vitamins and supplements, and oral hygiene products. Additionally, PGHL benefits from strategic partnerships with healthcare providers and organizations that enhance product visibility and consumer trust. The company's strong brand equity and continued investment in research and development also contribute significantly to its earnings by ensuring a steady pipeline of innovative health solutions.

Procter & Gamble Health Ltd. Financial Statement Overview

Summary

Procter & Gamble Health Ltd. exhibits a strong financial position across all verticals. The income statement reflects robust profitability and growth, while the balance sheet indicates excellent financial stability with low leverage. The cash flow statement is positive, with strong cash generation capabilities. The company is well-positioned for future growth, though there is room for improvement in cost management and operational efficiency.

Income Statement

Procter & Gamble Health Ltd. demonstrates strong profitability with a consistent increase in net profit margin and EBIT margin over the years. The company has shown a healthy revenue growth rate of 7.42% in the most recent year, indicating robust sales performance. However, the gross profit margin has declined slightly, suggesting increased cost pressures. Overall, the income statement reflects a solid financial performance with room for improvement in cost management.

Balance Sheet

The balance sheet of Procter & Gamble Health Ltd. is very strong, characterized by a low debt-to-equity ratio of 0.014, indicating minimal leverage and financial risk. The return on equity is impressive at 58.21%, showcasing efficient use of shareholder funds to generate profits. The equity ratio is healthy, reflecting a strong capital structure. Overall, the balance sheet is robust, with excellent financial stability and low risk.

Cash Flow

The cash flow statement shows a positive trajectory with strong free cash flow to net income ratio of 0.95, indicating efficient cash generation relative to net income. The operating cash flow to net income ratio is slightly lower at 0.82, suggesting room for improvement in operational efficiency. The free cash flow growth rate is exceptionally high, but this is due to a low base effect. Overall, the cash flow position is solid, with potential for enhanced operational cash flow management.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	12.18B	12.46B	11.51B	12.30B	10.92B	9.91B
Gross Profit	7.69B	6.84B	8.21B	8.68B	7.25B	6.52B
EBITDA	3.59B	4.38B	3.07B	3.43B	2.81B	2.64B
Net Income	2.51B	3.13B	2.01B	2.29B	1.93B	1.77B
Balance Sheet
Total Assets	7.94B	7.94B	7.94B	11.01B	8.94B	9.86B
Cash, Cash Equivalents and Short-Term Investments	2.06B	1.89B	2.44B	4.53B	3.19B	4.64B
Total Debt	76.20M	76.20M	95.60M	120.00M	28.30M	76.10M
Total Liabilities	2.57B	2.57B	2.56B	3.50B	2.77B	2.82B
Stockholders Equity	5.37B	5.37B	5.38B	7.51B	6.16B	7.04B
Cash Flow
Free Cash Flow	459.90M	1.67B	2.07B	1.94B	1.32B	1.95B
Operating Cash Flow	492.20M	1.76B	2.28B	2.36B	1.70B	2.47B
Investing Cash Flow	-500.00K	24.40M	-68.70M	-215.00M	-255.40M	-322.70M
Financing Cash Flow	-1.34B	-2.35B	-4.18B	-984.70M	-2.89B	-3.87B

Procter & Gamble Health Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6215.80
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PGHL, the sentiment is Positive. The current price of 6215.8 is below the 20-day moving average (MA) of 6241.30, below the 50-day MA of 6288.21, and above the 200-day MA of 5612.18, indicating a neutral trend. The MACD of -25.84 indicates Positive momentum. The RSI at 48.82 is Neutral, neither overbought nor oversold. The STOCH value of 60.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:PGHL.

Procter & Gamble Health Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PGHL	75 Outperform	₹103.18B	34.33	―	2.97%	2.37%	23.22%
ZYDUSWELL	73 Outperform	₹146.53B	44.80	―	0.26%	10.63%	7.53%
JYOTHYLAB	68 Neutral	₹116.22B	31.80	―	1.10%	1.59%	-2.52%
SURYAROSNI	68 Neutral	₹60.32B	20.95	―	1.54%	-8.69%	-20.94%
SYMPHONY	67 Neutral	₹61.64B	36.91	―	1.45%	-6.43%	-20.90%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
EVEREADY	57 Neutral	₹26.71B	32.06	―	0.41%	5.32%	16.91%